Rociletinib (CO-1686) is an Orally Active EGFR-Mutant Inhibitor
NSCLC accounts for almost 85% of all lung cancers. Additionally, lung cancer continues to be the most common cause of cancer-related deaths worldwide. Activating mutations in the epidermal growth factor…